The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

Shanghai, China & JERSEY CITY, N.J., United States: ...

Bio-Thera and Dr. Reddy's partner for biosimilar commercialization in Southeast Asia, expanding access to affordable ...

Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) of its operating company Fresenius Kabi, has ...

The formulation comparison between a biosimilar and a branded biologic. The cost, availability, and supply chain benefits of ...

Biosimilars can not only reduce patients' financial burdens, but also encourage more people to go for early diagnosis and comprehensive treatment ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

The tariff increase is anticipated to result in higher drug costs and, in the medium term, increased insurance premiums for ...

Commentary: New York must take on Big Pharma by demanding more transparency in pricing and ensuring generics aren't delayed ...